Overview

A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)

Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
A Phase 2, multicenter, adaptive 2-part clinical trial designed to evaluate the safety and efficacy of ADX-629 alone and in combination with standard-of-care in adults with atopic dermatitis.
Phase:
Phase 2
Details
Lead Sponsor:
Aldeyra Therapeutics, Inc.